PacBio Unveils TRGT, A Tool For Characterizing Rare Disease
Executive Summary
PacBio's TRGT can sequence broader sections of DNA, giving scientists and clinicians better odds of spotting repeated sections of DNA linked to disease.
You may also be interested in...
Exec Chat: PacBio Addresses Latest Results, New Tech And Long-Read Sequencing’s Future
PacBio has been burning through investors’ cash as it works to make long-read sequencing more accessible. Neil Ward, the company’s general manager, laid out his thoughts on the technology, its place in the market and how genomics data can be both effectively and fairly utilized.
Minute Insight: SpectralMD Signs Another Contract With BARDA, Worth $149m
The diagnostic company has secured more government funding for DeepView, a product it has developed to assess the healing of certain types of wound. In total, BARDA has supported SpectralMD with almost a quarter of a billion dollars.
Minute Insight: Vicarious’ Future Gets Precarious
The surgical robotics start-up may be de-listed from the New York Stock Exchange (NYSE) due to its low current share price. Some analysts believe the company can survive long enough to earn FDA de novo clearance for its robotic surgical system.